1. Home
  2. FLNT vs BMEA Comparison

FLNT vs BMEA Comparison

Compare FLNT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluent Inc.

FLNT

Fluent Inc.

HOLD

Current Price

$3.35

Market Cap

102.0M

ML Signal

HOLD

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.26

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNT
BMEA
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.0M
91.1M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
FLNT
BMEA
Price
$3.35
$1.26
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$3.50
$9.83
AVG Volume (30 Days)
23.9K
843.8K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
41.67
69.19
EPS
N/A
N/A
Revenue
$208,764,000.00
N/A
Revenue This Year
$5.89
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.87
52 Week High
$4.15
$2.99

Technical Indicators

Market Signals
Indicator
FLNT
BMEA
Relative Strength Index (RSI) 49.40 46.75
Support Level $3.39 $1.23
Resistance Level $3.52 $1.46
Average True Range (ATR) 0.22 0.07
MACD -0.07 -0.00
Stochastic Oscillator 11.84 34.09

Price Performance

Historical Comparison
FLNT
BMEA

About FLNT Fluent Inc.

Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: